Novo Nordisk acquires Emisphere Technologies for $1.8 billion. The deal will allow the company to obtain the rights to Emisphere Eligen SNAC technology, which it successfully uses in the production of Rybelsus and not to pay royalties for it. The purchase will be financed by borrowed funds.